Related Experiment Video
Updated: Jan 28, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Lipoprotein(a) and mortality-a high risk relationship
Reinhard Klingel1,2, Andreas Heibges3, Cordula Fassbender3
1Apheresis Research Institute, Stadtwaldguertel 77, 50935, Cologne, Germany. klingel@apheresis-research.org.
Insights
High lipoprotein(a) (Lp(a)) levels are linked to atherosclerotic cardiovascular disease (ASCVD) risk. Further research is needed to confirm if reducing Lp(a) lowers cardiovascular mortality, especially alongside LDL-C lowering therapies.
Area of Science:
- Cardiology
- Genetics
- Biochemistry
Background:
- Lipoprotein(a) (Lp(a)) is an established, independent risk factor for atherosclerotic cardiovascular disease (ASCVD).
- Elevated Lp(a) levels, or Lp(a)-hyperlipoproteinemia (Lp(a)-HLP), are associated with early or progressive ASCVD and familial predispositions.
- The German guideline for lipoprotein apheresis in Lp(a)-HLP patients identifies high-risk individuals using Lp(a) thresholds and ASCVD progression despite LDL-C therapy.
Purpose of the Study:
- To investigate the plausible link between Lp(a)-associated risk and increased cardiovascular mortality.
- To address inconsistencies in existing studies regarding Lp(a) concentration and mortality.
- To highlight the need for prospective evaluations on the impact of combined Lp(a) and LDL-C lowering therapies on mortality.
Main Methods:
- Review of existing investigations on Lp(a) concentration and mortality.
- Analysis of factors potentially influencing study outcomes, such as population genetic homogeneity and follow-up duration.
- Consideration of the interplay between LDL-C levels, LDL-C lowering treatments, and Lp(a) risk.
Main Results:
- A majority of studies demonstrate an association between Lp(a) concentration and total or cardiovascular mortality.
- Inconsistency exists in study findings, lacking a clear trend to explain variations.
- Lp(a) and LDL particles exhibit a mutual effect modification on ASCVD risk.
Conclusions:
- Lp(a) concentration may significantly increase cardiovascular mortality, particularly in specific patient groups.
- Genetic homogeneity, long-term follow-up, and patient selection are crucial for clarifying Lp(a)'s impact on ASCVD progression and mortality.
- Prospective studies are essential to validate whether targeted Lp(a) reduction, in addition to LDL-C lowering, effectively reduces cardiovascular and total mortality.
Abstract:
Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor playing a causal role for atherosclerotic cardiovascular disease (ASCVD). Early or progressive ASCVD or a familial predisposition are key findings which can be associated with Lp(a)-hyperlipoproteinemia (Lp(a)-HLP). The German guideline for the indication of lipoprotein apheresis in patients with Lp(a)-HLP has proved to be of value to identify patients at highest risk, using the composite of a Lp(a) threshold >60 mg/dl (>120 nmol/l) and clinical ASCVD progression despite effective LDL-C lowering therapy. In particular for such patients it appears to be plausible that Lp(a)-associated risk would increase cardiovascular mortality as the most important part of total mortality in Western populations. By the majority of existing investigations an association of Lp(a) concentration on total or cardiovascular mortality was demonstrated. However, inconsistency in the findings between studies exists without a clear trend for any study feature to explain this. Genetic homogeneity of the population, long-term follow-up, and clinically guided selection of patients might be important to further clarify the impact of Lp(a) concentration on progression of ASCVD, and finally total or cardiovascular mortality. LDL and Lp(a) particles exhibit a mutual effect modification on related ASCVD risk. Therefore, LDL-C levels and concomitant LDL-C lowering treatment must be considered in this context. Prospective evaluation is needed to document that specific Lp(a)-lowering additional to targeted LDL-C lowering will in fact reduce cardiovascular or total mortality.
Related Concept Videos
Relationship Formation
Ending Relationships
Relationship Growth
Relative Risk
Social Relationships and Well-Being
Close Relationships and Culture

